Nelson pharmacy fined $344,000 and director $50,000 for price-fixing

Miragenews | June 07, 2020

Nelson pharmacy fined $344,000 and director $50,000 for price-fixing
The Wellington High Court has ordered Prices Pharmacy 2011 Limited and a director of the company, Stuart Hebberd, to pay fines of $344,000 and $50,000 respectively, after they admitted engaging in price-fixing in breach of the Commerce Act. The Commission filed proceedings in April 2018 alleging that Prices Pharmacy 2011 Limited and its directors facilitated a price-fixing arrangement with competing Nelson pharmacies in May 2016, in breach of Part 2 of the Commerce Act. In most cases, the arrangement resulted in consumers paying $6, instead of $5, for their prescription items.

Spotlight

The calibrant region is determined automatically. The mass calibration function and its ideal polynomial degree are selected automatically using an information criterion to avoid over-fi tting. No manual recalibration is necessary. Novel isotope pattern validation procedure A statistical evaluation of isotopic distributions from all individual mass spectra in the elution time range of the target and adducts is done.

Spotlight

The calibrant region is determined automatically. The mass calibration function and its ideal polynomial degree are selected automatically using an information criterion to avoid over-fi tting. No manual recalibration is necessary. Novel isotope pattern validation procedure A statistical evaluation of isotopic distributions from all individual mass spectra in the elution time range of the target and adducts is done.

Related News

Additive Orthopaedics® Announces additive manufacturing Capability with Patient Specific Implant Locking Technology

Additive Orthopaedics, LLC | October 23, 2020

Additive Orthopaedics, LLC., the leader in 3D printed orthopaedic foot and ankle devices, announces a novel breakthrough in orthopaedic additive manufacturing with their ability to incorporate locking technology in all of their Patient Specific Implants. The patent pending technology can be incorporated in Additive Orthopaedics Patient Specific 3D Printed Plates and Patient Specific 3D Printed Bone Segments. According to Luciano Bertolotti, Director of Engineering for Additive Orthopaedics, "Locking technology is straightforward for off the shelf implants in which the machining process for the screw hole threads is set up once and can be manufactured in high volumes.

Read More

RESEARCH

Gilead gets WHO cold shoulder for remdesivir in COVID-19, launches speedy defense

Gilead | November 21, 2020

Gilead Sciences’ Veklury, better known as remdesivir, is so far the only COVID-19 therapy officially approved by the FDA, but the World Health Organization has some other ideas about the drug’s worth. At clear odds with the FDA’s approval, the WHO has for now recommended against the use of remdesivir in any hospitalized patients—regardless of disease severity—after an expert panel said it had found no evidence that remdesivir has any meaningful effect on saving lives and other important outcomes for patients, the international body said Thursday. A “disappointed” Gilead immediately fought back. It pointed to remdesivir’s inclusion in several other organizations’ guidelines based on data from a phase 3 trial by the National Institute of Allergy and Infectious Diseases (NIAID), which showed the drug’s use could lead to faster recovery.

Read More

Coronavirus Vaccine: Johnson & Johnson Pledges 100M Doses to U.S. For $10 Each

Johnson & Johnson | August 06, 2020

With leading COVID-19 vaccines in late-stage testing, companies have been inking supply deals with the U.S. government for a quick rollout if their programs succeed. Now, Johnson & Johnson is getting into the act. The pharma giant struck a deal to supply 100 million doses of its candidate, Ad26.COV2.S, if the shot is cleared for use by the FDA. The U.S. government is committing just over $1 billion under the agreement for a price per dose of about $10. That compares with a lower price-per-dose of $4 for AstraZeneca and a higher figure of $19.50 for Pfizer and BioNTech under agreements between those drugmakers and the U.S. government. J&J and AZ have pledged to provide their vaccines under a not-for-profit basis during the pandemic. Under the new J&J deal, which stipulates manufacturing in the U.S., the feds could later buy another 200 million doses under a separate agreement. The company previously won $456 million in funding to support its R&D and manufacturing scale-up, according to a government database.

Read More